AbbVie Inc. $ABBV Shares Sold by AlphaQuest LLC

AlphaQuest LLC lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 66.2% in the third quarter, HoldingsChannel.com reports. The firm owned 2,956 shares of the company’s stock after selling 5,787 shares during the period. AlphaQuest LLC’s holdings in AbbVie were worth $684,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in AbbVie by 1.9% in the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock worth $32,910,186,000 after acquiring an additional 3,380,842 shares during the last quarter. Geode Capital Management LLC raised its position in shares of AbbVie by 2.4% during the 2nd quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock worth $7,240,169,000 after purchasing an additional 924,761 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of AbbVie by 6.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock worth $4,970,848,000 after purchasing an additional 1,517,222 shares during the last quarter. Norges Bank bought a new stake in shares of AbbVie in the 2nd quarter worth approximately $4,288,200,000. Finally, Raymond James Financial Inc. boosted its position in AbbVie by 41.8% during the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after purchasing an additional 2,753,312 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $225.53 on Wednesday. The stock has a market cap of $398.60 billion, a price-to-earnings ratio of 170.86, a PEG ratio of 0.93 and a beta of 0.35. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The stock’s 50 day moving average price is $224.20 and its 200 day moving average price is $219.16.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Regulatory progress: AbbVie submitted applications to the FDA and EMA seeking approval for upadacitinib (RINVOQ) in adults and adolescents with vitiligo after positive Phase 3 Viti‑Up results. Approval would create the first systemic treatment option for vitiligo and materially expand RINVOQ’s addressable market. AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ) in Adults and Adolescents With Vitiligo
• Positive Sentiment: Post‑Humira growth roadmap: Management is emphasizing growth from RINVOQ label expansion and cell therapy investments to replace declining Humira sales — a strategic narrative investors view as critical to sustaining revenue and EPS over the medium term. AbbVie Targets Post Humira Growth With Cell Therapy And RINVOQ Expansion
• Positive Sentiment: Analyst tone ahead of Q4 is constructive: Several previews and analyst notes expect a return to profit and cite Skyrizi/RINVOQ strength, prompting some buy recommendations ahead of earnings. Positive analyst positioning can support the stock into the report. Buy AbbVie Stock Before Q4 Earnings? Here’s What to Know
• Positive Sentiment: Market narratives remain bullish on long-term upside and dividend quality after AbbVie navigated the Humira patent cliff — supporting investor confidence in total returns. 2 Healthcare Dividend Stocks That are Just What the Doctor Ordered
• Neutral Sentiment: Earnings preview/expectations: Multiple previews (Seeking Alpha, MarketWatch, Yahoo) expect revenue growth and a Q4 swing to profit — the print and management commentary will be the immediate catalyst for volatility. AbbVie Q4 Preview: Here’s what to expect
• Neutral Sentiment: Marketing/business updates are ongoing but lower impact: Allergan Aesthetics and migraine education campaigns support brand and aesthetics business engagement, but are unlikely to move near‑term revenue materially. Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program
• Negative Sentiment: Relative performance concerns: Data show AbbVie underperformed some peers despite intraday gains, a signal that investors are weighing competitive dynamics and pipeline execution versus peers. Short‑term flows could pressure the stock if the upcoming print disappoints. AbbVie Inc. stock underperforms Monday when compared to competitors despite daily gains
• Negative Sentiment: Policy and pricing risk: Coverage on a large drug‑pricing pact and broader policy shifts highlights ongoing pricing/regulatory risks that could weigh on long‑term margins if unfavorable terms or reimbursement pressures intensify. Monitor policy developments closely. AbbVie’s US$100b Drug Pricing Pact Reshapes Growth And Policy Outlook

Analyst Ratings Changes

Several equities research analysts have weighed in on ABBV shares. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Piper Sandler reaffirmed an “overweight” rating and issued a $289.00 price objective (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Hsbc Global Res upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 10th. Finally, UBS Group restated a “neutral” rating on shares of AbbVie in a research note on Tuesday, January 13th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average target price of $251.17.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.